Hexima Limited is a biotechnology firm focused on the discovery and advancement of plant-derived proteins and peptides for medical applications in humans. Its primary drug candidate, pezadeftide, a plant defensin, is presently undergoing Phase IIb clinical evaluations in Australia and New Zealand to address fungal toenail infections. The company was established in 1997 and its main operations are situated in Preston, Australia.
Subscribe to see HEXIMA LIMITED.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
HEXIMA LIMITED. is a pharmaceuticals, biotechnology & life sciences company headquartered in Preston, Australia. Xcout tracks 11 named people at HEXIMA LIMITED., including Thomas C. Gentile (Chief Executive Officer, President & Chairman).
5 more named people on record for HEXIMA LIMITED., with roles, board committees and tenure — see the full roster →
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.